Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35

Maxim Group analyst Michael Okunewitch has initiated coverage on Kyntra Bio (NASDAQ: KYNB) with a Buy rating. The firm has set a price target of $35 for the stock.